-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Quest Diagnostics (DGX) delivered strong Q1 results with revenue of $2.895B, up 9.2% Y/Y, as robust requisition volume grew 10.9% (+10.8% organic) across its physician, hospital, and consumer segments. Diagnostic Information Services sales rose 9.4% while the adjusted operating margin improved modestly to 15.4% from 15.3% in the prior year. The company demonstrated progress in Advanced Diagnostics with strong demand for AD-Detect Alzheimer's blood tests and launched its AI Companion tool with 350,000 patient engagements since rollout. Management raised 2026 guidance, with the sales growth midpoint rising 0.7% to $11.84B and the adjusted EPS midpoint increasing 1.2% to $10.73, reflecting 7.3% and 8.9% growth, respectively, versus 2025. We await further details on DGX's progress in dialysis lab and water-purity testing services, as well as updates on its questhealth.com consumer channel development in the upcoming earnings call. Shares traded up approximately 3% in premarket action following the strong results.